Green tea extract can keep CLL patients inhibited cancer cells

In phase II trials, a green tea extract appears to have low toxicity and anticancer activity in patients with chronic lymphoblastic leukemia (CLL), according to researchers at the Mayo Clinic and medical center A series of recent studies in the clinic have shown that the chemical catechinate (EGCG), the main component of green tea, is expected to be used to reduce the number of leukemia cells in patients with chronic lymphocytic leukemia The results of the study were presented at the annual meeting of the American Society for Clinical Oncology (ASCO) on June 7 The Mayo Clinic and medical center took the lead in many laboratory tests of EGCG eight years ago, and found that EGCG can reduce the survival of CLL leukemia cells Therefore, phase I clinical trial followed the results of this laboratory study - this is the first time to use green tea extract to study patients with chronic lymphoblastic leukemia "Although only the corresponding phase III clinical trial can determine whether EGCG can delay the normal development of chronic lymphocytic leukemia, however, the benefits we see in most CLL patients using the drug indicate that it has moderate clinical activity and may help stabilize or even slow down the development of the disease." Said Dr Tait shanafelt, a hematologist at Mayo Clinic and medical center who led the study "These studies raise the idea that, like EGCG, functional foods can and should be studied as a way to prevent cancer." Said Dr Neil Kay, a hematologist at the center Moreover, his laboratory took the lead in the experiment of green tea extract in leukemia blood cells of CLL patients, he said: "in oncology research, it is a valuable target to use non-toxic chemicals to delay tumor growth and thus the demand for toxic treatment, especially for CLL." However, Dr shanafelt and Dr Kay also stressed that EGCG cannot replace chemotherapy All patients in Mayo clinical and medical center study are in early stage, while asymptomatic early CLL patients do not need to be treated before the disease further develops.